Raritan, NJ-The FDA has approved a once-a-day liquid formulation of the fluoroquinone antibiotic levofloxacin (Levaquin), from Ortho-McNeil Pharmaceutical, Inc. Levofloxacin is indicated for the treatment of a number of infections, including complicated and uncomplicated urinary tract infections, chronic bacterial prostatitis, and acute pyelonephritis.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.